Ocugen (OCGN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +16.67%. A quarter ago, it was expected that this biotech knee implant developer would post a loss of $0.06 per share when it actually produced a loss of $0.05, delivering a surprise of +16.67%.Over the last four quarters, the co ...

Moderna (MRNA) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $2.99. This compares to a loss of $3.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +28.76%. A quarter ago, it was expected that this biotechnology company would post a loss of $2.92 per share when it actually produced a loss of $2.52, delivering a surprise of +13.7%.Over the last four quarters, the company has ...

财务表现 - 公司季度每股收益为1.58美元，远超Zacks一致预期的亏损0.3美元，去年同期亏损0.79美元，经非经常性项目调整后，盈利超预期幅度达626.67% [1] - 季度营收达1.4362亿美元，同比从125万美元大幅增长，超出市场预期4,388.22% [2] - 过去四个季度中，公司两次超过每股收益预期，两次超过营收预期 [2] 市场表现与预期 - 公司股价年初至今下跌79.4%，同期标普500指数上涨8.2% [3] - 当前Zacks评级为5级（强烈卖出），因财报发布前盈利预期修正趋势不利 [6] - 下一季度共识预期为每股亏损0.31美元、营收321万美元，本财年预期每股亏损1.65美元、营收175万美元 [7] 行业对比 - 所属医疗-生物医学与遗传学行业在Zacks行业排名中处于后41%分位，历史数据显示前50%行业表现是后50%的2倍以上 [8] - 同行Tango Therapeutics预计季度每股亏损0.35美元（同比恶化45.8%），营收619万美元（同比下滑68.9%） [9][10] 未来关注点 - 管理层在财报电话会中的评论将影响股价短期走势 [3] - 投资者需跟踪后续季度盈利预期修正趋势，其与股价变动存在强相关性 [5]

Illumina (ILMN) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +16.67%. A quarter ago, it was expected that this genetic testing tools company would post earnings of $0.96 per share when it actually produced earnings of $0.97, delivering a surprise of +1.04%.Over the last four quarte ...

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50.00%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.08 per share when it actually produced earnings of $0.03, delivering a surprise of -62.5%.Over the last four qu ...

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $2.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +36.45%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $1.51 per share when it actually produced earnings of $1.8, delivering a surprise of +19.21%.Over the last four ...

Novavax (NVAX) ended the recent trading session at $6.85, demonstrating a -2.28% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.13%. At the same time, the Dow lost 0.39%, and the tech-heavy Nasdaq gained 0.15%. Heading into today, shares of the vaccine maker had gained 6.05% over the past month, outpacing the Medical sector's loss of 0.96% and the S&P 500's gain of 3.39%.Analysts and investors alike will be keeping a close eye on the performance of Novavax in i ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $5.81, demonstrating a -2.35% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.13%. Meanwhile, the Dow experienced a drop of 0.39%, and the technology-dominated Nasdaq saw an increase of 0.15%. The stock of biotechnology company has risen by 15.98% in the past month, leading the Medical sector's loss of 0.96% and the S&P 500's gain of 3.39%.Analysts and investors alike will be keeping a close ...

The market expects Vir Biotechnology, Inc. (VIR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 6, might help the stock move higher if these key numbers a ...

GSK (GSK) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +9.82%. A quarter ago, it was expected that this drug developer would post earnings of $1.08 per share when it actually produced earnings of $1.13, delivering a surprise of +4.63%.Over the last four quarters, the company has su ...